semaglutide and cardiovascular outcomes in obesity without diabetes π βοΈIn patients with preexisting cardiovascular disease and overweight or obesity but without diabetes, weekly subcutaneous semaglutide at a dose of 2.4 mg was SELECT Trial
Description
This advanced formula provides 500 million AFU of Akkermansia muciniphila plus chicory inulin, a prebiotic fiber that helps nourish beneficial gut microbes
Patient-derived human islets from male and female cadaveric donors were 3D-cultured in solubilised extracellular matrix gel in co-culture with the same donor PBMCs, and incubated with cytokines (IL-1, TNF-, IFN-) for 2448 h in the presence of vehicle or increasing concentrations of the CB1R blocker JD-5037
Discover how pasta can support your body while on GLP-1 medications
Learn why it happens and practical ways to manage it.
